Oncolytics Biotech announces positive data from Resolysin clinical trial Oncolytics Biotech announced that an abstract detailing early results from translational study looking at the intravenous administration of REOLYSIN to patients with primary or metastatic brain tumors is now available on the ASCO Annual Meeting abstract website. The conference is being held from May 30th to June 3rd Chicago, Illinois. The abstract, titled "Oncolytic wild-type reovirus infection in brain tumors following intravenous administration in patients," contends that intravenous delivery to brain tumors would be easier, cheaper and more acceptable to patients than intralesional administration.
News For ONCY From The Last 14 Days
Check below for free stories on ONCY the last two weeks.